KOSPIChemicals005950

ISU Chemical

₩8,750▼ 0.23%2026-11-18 close
Market Cap
₩230.1B
Turnover
₩2.5B
Volume
290K
Shares out.
26.3M
PER
2.1×
PBR
1.1×
EPS
₩4,074
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Tight LAB Supply Lifts Profit; Durability in Focus

ISU Chemical's quarterly operating profit rose sharply in 2026 as Middle East disruption tightened LAB supply, but because earnings lean heavily on the raw-material price spread, its post-conflict earnings structure is the next checkpoint.

  1. 1

    Operating profit was KRW 25.4 billion in 1Q26, KRW 96.6 billion in 2Q26 and KRW 42.2 billion in 3Q26, all profitable, after an operating loss of KRW 3.41 billion in 4Q25.

  2. 2

    Attributable net income was a loss in each year from 2023 through 2025, and the operating margin was 0.4% in 2025.

  3. 3

    According to the company's November 2026 release, the debt-to-equity ratio fell to 141% at end-September from 305.0% at end-2025.

  4. 4

    NP supply disruption and a wider LAB-NP price spread are cited as drivers, and press reports expect LAB prices to fall once the conflict ends.

  5. 5

    Attributable net income over the last four quarters totals KRW 107.8 billion, but the window includes a KRW 13.2 billion loss in 4Q25, so quarterly swings are large.

02

Business structure

ISU Chemical is a petrochemical company whose main product is linear alkylbenzene (LAB), a raw material for synthetic detergents. Reports describe it as the only LAB producer in Korea. LAB is a key input for surfactants used in products such as laundry detergent.

The company sources kerosene from an external refiner, extracts normal paraffin (NP) from it, and processes NP into LAB in an integrated production chain.

Because raw-material sourcing and product supply run in one flow, the company says it kept producing and supplying even when Middle East disruption unsettled feedstock.

At its 2025 results release, the company said LAB and NP had become specialty products growing steadily, and that it had adjusted regional sales portfolios to seize market opportunities. At its 3Q26 release, the company said a profit-focused sales strategy lifted earnings.

Its consolidated construction subsidiary has kept posting profits by growing public building projects with secured profitability, and the company announced that the subsidiary returned to operating profit in 1Q26.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩441.8B₩6.4B1.4%
2025Q4₩477.2B-₩3.4B−0.7%
2026Q1₩635.9B₩25.4B4.0%
2026Q2₩743.4B₩96.6B13.0%
2026Q3₩684.7B₩42.2B6.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.2T₩36B₩27.7B1.6%9.1%193.0%
2023₩2T-₩56B-₩31.3B−2.8%−19.8%319.5%
2024₩1.9T-₩51.4B-₩47.4B−2.7%−45.4%331.7%
2025₩1.7T₩6.9B-₩31.1B0.4%−32.3%305.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a disclosed basis, revenue fell from KRW 2.21 trillion in 2022 to KRW 2 trillion in 2023 (down 9.6% year on year), KRW 1.92 trillion in 2024 (down 4.0%) and KRW 1.66 trillion in 2025 (down 13.4%), a decline in each year from 2023 through 2025. 2022 was the largest year and 2025 the smallest within 2022 to 2025.

Operating profit of KRW 36 billion in 2022 turned into an operating loss of KRW 56 billion in 2023, and the loss continued in 2024 at KRW 51.4 billion, narrowing from the prior year. In 2025 operating profit returned at KRW 6.88 billion, but the operating margin was only 0.4%.

Attributable net income fell from KRW 27.7 billion in 2022 to losses of KRW 31.3 billion in 2023, KRW 47.4 billion in 2024 and KRW 31.1 billion in 2025, three consecutive years of losses.

Net income including non-controlling interests also stayed negative, at losses of KRW 28.1 billion in 2023, KRW 38.2 billion in 2024 and KRW 40.5 billion in 2025.

Operating cash flow stayed negative at -KRW 33.3 billion in 2022, -KRW 75.2 billion in 2023 and -KRW 68.4 billion in 2024, then narrowed sharply to -KRW 4.3 billion in 2025.

Quarterly, operating profit of KRW 6.37 billion in 3Q25 gave way to an operating loss of KRW 3.41 billion in 4Q25, a swing into loss from the prior quarter. Operating profit then recovered to KRW 25.4 billion in 1Q26, KRW 96.6 billion in 2Q26 (up 279.7% from the prior quarter) and KRW 42.2 billion in 3Q26.

Revenue of KRW 684.7 billion in 3Q26 fell 7.9% from the prior quarter but rose 55.0% year on year, while attributable net income of KRW 23.4 billion fell 69.3% from the prior quarter.

The debt-to-equity ratio was 305.0% at end-2025, and the company says it fell to 141% at end-September 2026, reflecting higher profit and lower borrowings.

05

Industry analysis

Demand for LAB tracks consumption of synthetic detergents, and since the Middle East disruption, feedstock supply shortfalls have pushed product prices up.

According to a Korean business daily report, the Middle East accounts for 10 to 20 percent of the global NP market, and the conflict disrupted Middle East NP supply, sending LAB prices sharply higher.

The same report, citing a domestic brokerage research report, said the average LAB-NP price spread for March to September 2026 widened to USD 981 per ton, 2.5 times the USD 390 average of the 12 months before the war.

Because this spread was the key driver of profit, whether it holds is the central question for the sector. Meanwhile, according to the same report, the petrochemical industry has been in a prolonged slump driven by oversupply from China.

Reports also said several major domestic petrochemical companies posted large losses in 3Q26. The company says global LAB capacity is being reshaped by new plants in the Middle East and Asia and plant closures in Europe.

As the only LAB producer in Korea, ISU Chemical's NP sourcing and integrated production are cited as differentiators. However, its NP feedstock depends on kerosene supplied by an outside refiner, leaving concentrated raw-material risk.

06

Outlook

At its 3Q26 release, the company stated its aim to sustain the high-profit run through year-end and deliver meaningful results for the full year. At its 1Q26 release, the company said it expected supply tightness linked to the Middle East situation to continue into 2Q26.

Operating profit did rise to KRW 96.6 billion in 2Q26 from KRW 25.4 billion in 1Q26, and first-half operating profit of KRW 122 billion was reported in the press as a record. However, a Korean business daily reported that LAB prices are expected to fall once the war ends.

Accordingly, the direction of earnings after 4Q26 depends on how the Middle East situation and the LAB-NP price spread move. On the balance sheet, guarantees the company provided for its construction subsidiary fell from KRW 98.6 billion at end-2025 to KRW 20.8 billion at end-1Q26, easing financial burden.

The company attributes the lower debt ratio to reduced borrowings. The company says it will continue profit-focused management and balance-sheet improvement. Results for 4Q26 will be formally disclosed with full-year figures in the 2026 annual business report.

07

Valuation

PER
2.1×
PBR
1.1×
ROE
70.0%
EPS
₩4,074
BPS
₩7,844
Dividend per share
₩0

Valuation should be read on both an earnings basis and an asset basis. Attributable net income over the last four quarters totals KRW 107.8 billion, but that window includes a KRW 13.2 billion loss in 4Q25, so quarterly swings are large.

Earnings-based multiples can move considerably on one or two quarters of results, so a single-point reading is hard to interpret. The price-to-book ratio sits in a range where the share price is slightly above book value per share.

Of the KRW 221.7 billion in total equity at end-2025, KRW 96.1 billion belonged to controlling shareholders, so the capital structure carries a large non-controlling interest, and asset value reads differently on an attributable basis versus a consolidated basis. Dividend payouts are effectively negligible.

Looking at the trend, the company moved from operating losses in 2023 and 2024 to an operating profit in 2025 and profitable quarters in 2026. The key variable for valuation is therefore whether this earnings recovery continues on an annual basis.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Profitable quarters restored

After an operating loss of KRW 3.41 billion in 4Q25, operating profit reached KRW 25.4 billion in 1Q26, KRW 96.6 billion in 2Q26 and KRW 42.2 billion in 3Q26, three straight profitable quarters. Operating profit in 2Q26 rose 279.7% from the prior quarter.

Press reports described first-half operating profit of KRW 122 billion as a record. Quarterly recovery in earnings power is cited as the core bullish point.

Balance-sheet improvement

According to the company's November 2026 release, the debt-to-equity ratio fell from 305% to 141% at end-September, and the current ratio rose from 81% to 124%. Guarantees for its construction subsidiary fell from KRW 98.6 billion at end-2025 to KRW 20.8 billion at end-1Q26. The company says lower borrowings widened its financial room.

Sole domestic LAB producer with integrated supply

ISU Chemical is the only LAB producer in Korea and runs an integrated chain from NP to LAB. The company says it kept stable supply during the Middle East disruption, which strengthened its market position. Supply stability emerging as a competitive factor in global LAB markets is also cited as a structural strength.

09

Bear factors

Reliance on Middle East disruption

A domestic brokerage report cited in the press put the LAB-NP average spread for March to September 2026 at USD 981 per ton, 2.5 times the USD 390 average of the 12 months before the war. Because profit could reverse as the spread narrows, this is a bearish factor. Press reports also expect LAB prices to fall once the war ends.

Weak petrochemical cycle

Amid a long slump in petrochemicals driven by Chinese oversupply, press reports said several major domestic petrochemical companies posted large losses in 3Q26. Because ISU Chemical's strong results stem from LAB-specific supply conditions rather than a broad sector recovery, this is a limiting factor.

Long-run earnings weakness

On a disclosed basis, attributable net income was a loss for three consecutive years from 2023 through 2025, and the 2025 operating margin was 0.4%. Of KRW 221.7 billion in total equity at end-2025, KRW 96.1 billion belonged to controlling shareholders. Operating cash flow was negative in all four years from 2022 through 2025.

10

Risk factors

Feedstock and geopolitical risk

LAB prices and NP supply move with Middle East conditions, and the price spread could narrow if the war ends or supply normalizes. Earnings are heavily exposed to external variables. The gap between 2Q26 operating profit of KRW 96.6 billion and 3Q26 operating profit of KRW 42.2 billion illustrates this volatility.

Cycle and spread-reversal risk

With the petrochemical cycle weak, a reversal between feedstock costs and selling prices could push the company back into quarterly losses. A loss quarter similar to the KRW 3.41 billion operating loss in 4Q25 could recur. Its quarterly record has already alternated between profit and loss.

Financial and subsidiary risk

Total liabilities at end-2025 were KRW 676.1 billion against total equity of KRW 221.7 billion, a heavy debt load. Guarantees of KRW 20.8 billion for the construction subsidiary remained at end-1Q26, so subsidiary earnings swings could affect consolidated finances.

11

What to watch next

  1. Early 2027

    4Q26 results will show whether the year-end high-profit run held relative to 3Q26 operating profit of KRW 42.2 billion. The company stated its aim to keep the high-profit run through year-end.

  2. End of March 2027

    The 2026 annual business report will finalize full-year revenue, operating profit and attributable net income. It will be read against the KRW 6.88 billion operating profit of 2025, along with the change in the debt ratio.

  3. Mid-May 2027

    1Q27 results will be compared with 1Q26 operating profit of KRW 25.4 billion. They will indicate where the LAB-NP price spread settles after Middle East conditions change.

  4. Ongoing, at each change in Middle East conditions

    Whether the war ends or supply normalizes is directly tied to expectations for lower LAB prices. Tracking the direction of the raw-material price spread is the starting point for interpreting upcoming results.

12

Overall view

ISU Chemical is the only LAB producer in Korea and runs an integrated chain from NP to LAB, and quarterly operating profit rose sharply in 2026 as Middle East disruption tightened LAB supply.

It was profitable in all three quarters, with KRW 25.4 billion in 1Q26, KRW 96.6 billion in 2Q26 and KRW 42.2 billion in 3Q26, and 3Q26 operating profit rose 563.2% year on year. On the balance sheet, the company says the debt-to-equity ratio fell to 141% at end-September, and guarantees for its subsidiary declined.

On a disclosed basis, however, attributable net income was a loss for three consecutive years from 2023 through 2025, and the 2025 operating margin was only 0.4%. Attributable net income over the last four quarters totals KRW 107.8 billion, yet that window includes a 4Q25 loss.

Because earnings lean heavily on the LAB-NP price spread, the direction of the Middle East situation and that spread is the key variable for the next results.

Industry-wide, the petrochemical sector is described as in a long slump driven by Chinese oversupply, so the durability of strong results depends on company-specific supply conditions.

The next checkpoints are 4Q26 results and the 2026 annual business report, and 1Q27 results will serve as the benchmark for earnings after the Middle East conflict.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. view.asiae.co.kr
  2. zdnet.co.kr
  3. m.inews24.com
  4. dailian.co.kr
  5. enewstoday.co.kr
  6. itbiznews.com
  7. medipharmhealth.co.kr
  8. hankyung.com
  9. isu.co.kr
  10. specialtimes.co.kr
  11. newspim.com
  12. vegannews.co.kr
  13. newspim.com
  14. g-enews.com
  15. m-i.kr
  16. stockray.app
  17. investing.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis